(-0.34%) 5 018.39 points
(0.23%) 37 903 points
(-0.33%) 15 605 points
(0.62%) $79.49
(1.19%) $1.955
(0.80%) $2 329.60
(0.34%) $26.84
(1.34%) $967.70
(0.03%) $0.933
(-0.01%) $11.03
(-0.07%) $0.798
(0.27%) $93.51
Live Chart Being Loaded With Signals
OSE Immunotherapeutics SA focuses on the development of immunotherapies for immune activation and regulation in the fields of immuno-oncology and autoimmune diseases...
Stats | |
---|---|
本日の出来高 | 95 863.00 |
平均出来高 | 146 280 |
時価総額 | 122.43M |
EPS | €0 ( 2024-04-21 ) |
次の収益日 | ( €0 ) 2024-06-21 |
Last Dividend | €0 ( N/A ) |
Next Dividend | €0 ( N/A ) |
P/E | -4.78 |
ATR14 | €0.0180 (0.32%) |
ボリューム 相関
Ose Immunotherapeutics SA 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Ose Immunotherapeutics SA 相関 - 通貨/商品
Ose Immunotherapeutics SA 財務諸表
Annual | 2023 |
収益: | €2.23M |
総利益: | €2.23M (100.00 %) |
EPS: | €-1.180 |
FY | 2023 |
収益: | €2.23M |
総利益: | €2.23M (100.00 %) |
EPS: | €-1.180 |
FY | 2022 |
収益: | €18.30M |
総利益: | €18.30M (100.00 %) |
EPS: | €-0.960 |
FY | 2021 |
収益: | €26.31M |
総利益: | €0.00 (0.00 %) |
EPS: | €-0.536 |
Financial Reports:
No articles found.
Ose Immunotherapeutics SA
OSE Immunotherapeutics SA focuses on the development of immunotherapies for immune activation and regulation in the fields of immuno-oncology and autoimmune diseases. Its products include Tedopi that is in Phase III clinical stage for the treatment of non-small cell lung cancer, as well as in Phase II clinical trial to pancreatic and ovarian cancer; CoVepiT, a prophylactic vaccine against the SARS-CoV-2 virus; BI 765063, which is in Phase I clinical trial to treat solid tumors; and BiCKI, a novel bispecific checkpoint inhibitor platform, targeting PD-1 and innovative targets to fight primary and secondary resistance mechanisms developed by cancers. The company's products also comprise OSE-127, a humanized monoclonal antibody that is in Phase II clinical trial for the treatment of ulcerative colitis, as well as Sjögren's Syndrome; FR104, which is in Phase I clinical trial for the treatment of rheumatoid arthritis; and OSE-230, an agonist antibody against ChemR23 to resolve chronic inflammation. OSE Immunotherapeutics SA has collaborations and partnerships with GERCOR, Boehringer Ingelheim, Servier, and Chong Kun Dang Pharmaceutical Corporation. The company was formerly known as OSE Pharma SA and changed its name to OSE Immunotherapeutics SA in May 2016. OSE Immunotherapeutics SA is headquartered in Nantes, France.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。